Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed ...

Pfizer CEO says tariffs are discouraging the company from investing in the US. Pfizer's full-year guidance does not factor in ...

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

Deloitte has committed to move its North American headquarters to Hudson Yards, the sprawling master-planned development on ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the U.S. – his administration’s bid to boost ...

Pfizer is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer (PFE) stock slips after the company's lower than expected Q1 2025 revenue and the firm seeks acquisitions to boost its ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer expects full-year earnings in the range of $2.80 to $3 per share, with revenue in the range of $61 billion to $64 billion. This story was generated by Automated Insights ( ...

(Reuters) -U.S. drugmaker Pfizer reported first-quarter profit above Wall Street estimates on Tuesday, helped by cots cuts ...